← Back to Search

Procedure

TMS for Stroke

N/A
Recruiting
Led By Alexander Opitz, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Prior occurrence of unprovoked seizure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying how using magnetic pulses can help improve movement in people who have had a stroke. The study aims to find the best way to use these pulses by looking at brain activity patterns during treatment. Magnetic pulses have been used in several medical and clinical research applications, including stroke treatment.

Who is the study for?
This trial is for individuals who have experienced a stroke over 6 months ago and are facing motor difficulties. Participants must be able to communicate in English. Those with metal or electric implants, recent botulinum toxin treatments in the upper extremities, current pregnancy or breastfeeding, or a history of seizures cannot join.
What is being tested?
The study is examining how transcranial magnetic stimulation (TMS) affects the excitability of the motor cortex in stroke survivors. It specifically looks at how different phases of brain wave rhythms influence this excitability.
What are the potential side effects?
TMS may cause discomfort at the stimulation site, headache, lightheadedness, or twitching of facial muscles during application. Rarely it can induce seizures but is generally considered safe.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a seizure without a known cause.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Motor evoked potentials (MEPs)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Participants Without Unilateral StrokeExperimental Treatment1 Intervention
Participants without self-reported unilateral stroke will take part in two experimental sessions: First, for assessment of stroke characteristics, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the lack of unilateral stroke will be confirmed. In participants without stroke, TMS will be applied targeting at the intensity of up to 120% resting motor threshold both left and right hemisphere.
Group II: Participants With Unilateral StrokeExperimental Treatment1 Intervention
Participants with self-reported unilateral stroke will take part in two experimental sessions: First, for assessment of stroke characteristics and MRI scan, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the unilateral stroke will be confirmed. In participants with stroke, TMS will be applied over the motor cortex on the affected and non-affected hemisphere at the intensity of up to 120% resting motor threshold.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial magnetic stimulation (TMS)
2013
Completed Phase 4
~540

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Stroke treatments generally aim to restore blood flow, protect brain tissue, and promote recovery of function. Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique that uses magnetic fields to stimulate nerve cells in the brain, particularly in the motor cortex. This stimulation can enhance neuroplasticity, which is the brain's ability to reorganize itself by forming new neural connections. For stroke patients, this is crucial as it can help in the recovery of motor functions that were impaired due to the stroke. By modulating neuronal activity, TMS can potentially improve motor control and reduce disability, making it a promising adjunctive therapy in stroke rehabilitation.

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,428 Previous Clinical Trials
1,620,832 Total Patients Enrolled
39 Trials studying Stroke
50,856 Patients Enrolled for Stroke
Alexander Opitz, PhDPrincipal InvestigatorUniversity of Minnesota Department of Biomedical Engineering
3 Previous Clinical Trials
42 Total Patients Enrolled

Media Library

TMS (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04968743 — N/A
Stroke Research Study Groups: Participants Without Unilateral Stroke, Participants With Unilateral Stroke
Stroke Clinical Trial 2023: TMS Highlights & Side Effects. Trial Name: NCT04968743 — N/A
TMS (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04968743 — N/A
~18 spots leftby Nov 2025